By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Washington State's Life Sciences Discovery Fund has awarded a $150,000 grant to a Fred Hutchinson Cancer Research Center scientist to fund a DNA sequencing technology that will be commercialized through a new company called Adaptive TCR Corporation.

The grant, which is part of a $600,000 LSDF program going to four Washington-based research teams, will be used to enhance a DNA sequencing technology that profiles T cells within the immune system.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by
Thermo Fisher Scientific

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.